

**BLAU FARMACÊUTICA S.A.**

Publicly Held Company  
NIRE 35.300.416.406  
CVM Code No. 2462-7

**NOTICE TO SHAREHOLDERS****Anticipation of the 1Q26 Earnings Release**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "**Blau**" or "**Company**"), informs its shareholders and the market in general that will anticipate its 1Q26 Earnings Release date, previously scheduled for May 12th 2026 and now to occur on **May 07th, 2026, after trading hours**. The webcast presentation will be held on May 08th, 2026 at 4 p.m. (Brasília time) / 3 p.m. (New York time).

Cotia, April 30, 2026

**Douglas Leandro Rodrigues**  
Chief Financial and Investor Relations Officer

**About Blau Farmacêutica:**

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.